205 related articles for article (PubMed ID: 27116211)
21. [Treatment of uveal melanoma with iodine 125 plaques or proton beam therapy: indications and comparison of local recurrence rates].
Desjardins L; Lumbroso L; Levy C; Mazal A; Delacroix S; Rosenwald JC; Dendale R; Plancher C; Asselain B
J Fr Ophtalmol; 2003 Mar; 26(3):269-76. PubMed ID: 12746603
[TBL] [Abstract][Full Text] [Related]
22. Repeat Episcleral Plaque Brachytherapy: Clinical Outcomes in Patients Treated for Locally Recurrent Posterior Uveal Melanoma.
King B; Morales-Tirado VM; Wynn HG; Gao BT; Ballo MT; Wilson MW
Am J Ophthalmol; 2017 Apr; 176():40-45. PubMed ID: 28048976
[TBL] [Abstract][Full Text] [Related]
23. Estimates of ocular and visual retention following treatment of extra-large uveal melanomas by proton beam radiotherapy.
Conway RM; Poothullil AM; Daftari IK; Weinberg V; Chung JE; O'Brien JM
Arch Ophthalmol; 2006 Jun; 124(6):838-43. PubMed ID: 16769837
[TBL] [Abstract][Full Text] [Related]
24. Intraocular inflammation after proton beam irradiation for uveal melanoma.
Lumbroso L; Desjardins L; Levy C; Plancher C; Frau E; D'Hermies F; Schlienger P; Mammar H; Delacroix S; Nauraye C; Ferrand R; Desblancs C; Mazal A; Asselain B
Br J Ophthalmol; 2001 Nov; 85(11):1305-8. PubMed ID: 11673294
[TBL] [Abstract][Full Text] [Related]
25. Long-term Risk of Melanoma-Related Mortality for Patients With Uveal Melanoma Treated With Proton Beam Therapy.
Lane AM; Kim IK; Gragoudas ES
JAMA Ophthalmol; 2015 Jul; 133(7):792-6. PubMed ID: 25905597
[TBL] [Abstract][Full Text] [Related]
26. Adjuvant Ab Interno Tumor Treatment After Proton Beam Irradiation.
Seibel I; Riechardt AI; Heufelder J; Cordini D; Joussen AM
Am J Ophthalmol; 2017 Jun; 178():94-100. PubMed ID: 28365241
[TBL] [Abstract][Full Text] [Related]
27. Effect of radiation dose on ocular complications after iodine brachytherapy for large uveal melanoma: empirical data and simulation of collimating plaques.
Puusaari I; Heikkonen J; Kivelä T
Invest Ophthalmol Vis Sci; 2004 Oct; 45(10):3425-34. PubMed ID: 15452045
[TBL] [Abstract][Full Text] [Related]
28. Neovascular glaucoma after proton beam therapy of choroidal melanoma: incidence and risk factors.
Riechardt AI; Pilger D; Cordini D; Seibel I; Gundlach E; Hager A; Joussen AM
Graefes Arch Clin Exp Ophthalmol; 2017 Nov; 255(11):2263-2269. PubMed ID: 28721444
[TBL] [Abstract][Full Text] [Related]
29. Intravitreal bevacizumab at 4-month intervals for prevention of macular edema after plaque radiotherapy of uveal melanoma.
Shah SU; Shields CL; Bianciotto CG; Iturralde J; Al-Dahmash SA; Say EAT; Badal J; Mashayekhi A; Shields JA
Ophthalmology; 2014 Jan; 121(1):269-275. PubMed ID: 24139123
[TBL] [Abstract][Full Text] [Related]
30. Posterior uveal melanoma in young patients treated with proton beam therapy.
Vavvas D; Kim I; Lane AM; Chaglassian A; Mukai S; Gragoudas E
Retina; 2010 Sep; 30(8):1267-71. PubMed ID: 20224468
[TBL] [Abstract][Full Text] [Related]
31. [Rapidly progressing cataract in contact with ciliary body melanoma after proton-beam irradiation].
Msika LC; Matet A; Dendale R; Vandermeer G; Levy C
J Fr Ophtalmol; 2019 Mar; 42(3):e115-e116. PubMed ID: 30833006
[No Abstract] [Full Text] [Related]
32. Temporal Evolution and Dose-Volume Histogram Predictors of Visual Acuity After Proton Beam Radiation Therapy of Uveal Melanoma.
Polishchuk AL; Mishra KK; Weinberg V; Daftari IK; Nguyen JM; Cole TB; Quivey JM; Phillips TL; Char DH
Int J Radiat Oncol Biol Phys; 2017 Jan; 97(1):91-97. PubMed ID: 27838186
[TBL] [Abstract][Full Text] [Related]
33. Helium-ion-induced human cataractogenesis.
Blakely EA; Daftari IK; Meecham WJ; Alonso LC; Collier JM; Kroll SM; Gillette EL; Lee AC; Lett JT; Cox AB; Castro JR; Char DH
Adv Space Res; 1994 Oct; 14(10):501-5. PubMed ID: 11539986
[TBL] [Abstract][Full Text] [Related]
34. Proliferative radiation retinopathy after plaque radiotherapy for uveal melanoma.
Bianciotto C; Shields CL; Pirondini C; Mashayekhi A; Furuta M; Shields JA
Ophthalmology; 2010 May; 117(5):1005-12. PubMed ID: 20079924
[TBL] [Abstract][Full Text] [Related]
35. Conservative management of suspicious melanocytic lesions of the iris.
Oxenreiter MM; Lane AM; Jain P; Kim IK; Gragoudas ES
Graefes Arch Clin Exp Ophthalmol; 2019 Jun; 257(6):1319-1324. PubMed ID: 30919077
[TBL] [Abstract][Full Text] [Related]
36. Corneal Substructure Dosimetry Predicts Corneal Toxicity in Patients With Uveal Melanoma Treated With Proton Beam Therapy.
Lee HJ; Stacey A; Klesert TR; Wells C; Skalet AH; Bloch C; Fung A; Bowen SR; Wong TP; Shibata D; Halasz LM; Rengan R
Int J Radiat Oncol Biol Phys; 2019 Jun; 104(2):374-382. PubMed ID: 30763658
[TBL] [Abstract][Full Text] [Related]
37. Iodine 125 brachytherapy with vitrectomy and silicone oil in the treatment of uveal melanoma: 1-to-1 matched case-control series.
McCannel TA; McCannel CA
Int J Radiat Oncol Biol Phys; 2014 Jun; 89(2):347-52. PubMed ID: 24721588
[TBL] [Abstract][Full Text] [Related]
38. Factors predictive of radiation retinopathy post (125)Iodine brachytherapy for uveal melanoma.
Krema H; Xu W; Payne D; Vasquez LM; Pavlin CJ; Simpson R
Can J Ophthalmol; 2011 Apr; 46(2):158-63. PubMed ID: 21708084
[TBL] [Abstract][Full Text] [Related]
39. Risk factors for cataract after palladium-103 ophthalmic plaque radiation therapy.
Finger PT; Chin KJ; Yu GP; Patel NS;
Int J Radiat Oncol Biol Phys; 2011 Jul; 80(3):800-6. PubMed ID: 20615627
[TBL] [Abstract][Full Text] [Related]
40. [Results of treating uveal melanoma with proton beam radiation: 10-year follow-up].
Hamrouni Z; Levy C; Lumbroso L; D'Hermies F; Frau E; Mazal A; Delacroix S; Nauraye C; Dendale R; Schlienger P; Desjardins L
J Fr Ophtalmol; 2005 Oct; 28(8):833-9. PubMed ID: 16249762
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
